The therapeutic community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 agonist that’s showing significant promise in clinical trials for treating obesity. Unlike some current weight loss solutions, retatrutide appears to deliver a more substantial loss in body